1h Free Analyst Time
The glioblastoma multiforme treatment market is forecasted to grow by USD 1.36 billion during 2023-2028, accelerating at a CAGR of 8.2% during the forecast period. The report on the glioblastoma multiforme treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing incidence of glioblastoma multiforme, favorable government initiatives for glioblastoma multiforme, and increasing geriatric population.
The glioblastoma multiforme treatment market is segmented as below:
By End-user
- Hospitals
- Clinics
- Ambulatory surgical centers
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the glioblastoma multiforme treatment market covers the following areas:
- Glioblastoma Multiforme Treatment Market sizing
- Glioblastoma Multiforme Treatment Market forecast
- Glioblastoma Multiforme Treatment Market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global glioblastoma multiforme treatment market: AIVITA Biomedical Inc., Amgen Inc., Amneal Pharmaceuticals Inc., Angiochem Inc., Arbor Pharmaceuticals LLC, AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Chimerix Inc., DNAtrix Inc., F. Hoffmann La Roche Ltd., Karyopharm Therapeutics Inc., Kazia Therapeutics Ltd., Medicenna Therapeutics Corp., Merck and Co. Inc., Pfizer Inc., Sumitomo Pharma Co. Ltd., and Sun Pharmaceutical Industries Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increasing research and development activities."
According to the report, one of the major drivers for this market is the increasing incidence of glioblastoma multiforme.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AIVITA Biomedical Inc.
- Amgen Inc.
- Amneal Pharmaceuticals Inc.
- Angiochem Inc.
- Arbor Pharmaceuticals LLC
- AstraZeneca Plc
- Bayer AG
- Bristol Myers Squibb Co.
- Chimerix Inc.
- DNAtrix Inc.
- F. Hoffmann La Roche Ltd.
- Karyopharm Therapeutics Inc.
- Kazia Therapeutics Ltd.
- Medicenna Therapeutics Corp.
- Merck and Co. Inc.
- Pfizer Inc.
- Sumitomo Pharma Co. Ltd.
- Sun Pharmaceutical Industries Ltd.
